Tolvaptan

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Uses

Tolvaptan can be used for euvolemic or hypervolemic hyponatremia.[1][2][3] However, vasopressin receptor antagonist may increase the frequency of rapid sodium correction although osmotic demyelination syndrome may not be increased.[1]

Tolvaptan can be used for heart failure.[4][5]

References

  1. 1.0 1.1 Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U (2010). "Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.". Am J Kidney Dis 56 (2): 325-37. DOI:10.1053/j.ajkd.2010.01.013. PMID 20538391. Research Blogging.
  2. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. (2006). "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.". N Engl J Med 355 (20): 2099-112. DOI:10.1056/NEJMoa065181. PMID 17105757. Research Blogging.
  3. (2009) Tolvaptan (Samsca) for Hyponatremia The Medical Letter
  4. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.". JAMA 297 (12): 1332-43. DOI:10.1001/jama.297.12.1332. PMID 17384438. Research Blogging.
  5. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.". JAMA 297 (12): 1319-31. DOI:10.1001/jama.297.12.1319. PMID 17384437. Research Blogging.